Ascenta Therapeutics, sanofi-aventis indication global licensing contract for cancer drug candidates Ascenta Therapeutics announced today the signing of a worldwide collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated because of their potential to revive tumor cell apoptosis . Under the conditions of the agreement, Ascenta Therapeutics has provided sanofi-aventis an exclusive worldwide license to develop, manufacture, and commercialize all compounds issued from this program pills intake . In return, Ascenta shall receive an upfront payment, as well as development, regulatory and industrial milestone obligations that could reach a total of $398 million.
Our clinical stage pipeline is now comprised of long-acting TransCon prodrugs that incorporate both small molecules and proteins, demonstrating the broader potential of the TransCon technology system. The Phase 1 study is an individual ascending dose research that will evaluate pharmacokinetic, injection tolerability, and safety parameters in a healthy volunteer population. Ascendis expects to report results from this scholarly study in mid-2015.. Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to handle significant unmet medical needs, today announced that it has initiated a Phase 1 single ascending dosage research of TransCon Treprostinil in healthy volunteers.